Trials / Unknown
UnknownNCT02882659
Dendritic Killer Cell-based Immunotherapy for Solid Tumors
Phase I Clinical Trial of Autologous Dendritic Killer Cell-based Immunotherapy for Solid Tumors
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- FullHope Biomedical Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the safety of autologous dendritic killer cell (DKC) in patients with metastatic solid tumor and to evaluate the maximum tolerated dose (MTD) of DKC. The primary endpoint of safety evaluation includes physical examination, assessment of vital sign, laboratory test, concomitant medication, and adverse event (AE). The secondary endpoints regarding efficacy includes the generation of tumor specific immune response by detecting CD3+ CD8+ CD69+ IFN-gamma+ T cells, and the improvement of quality of life
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Dendritic Killer Cell (DKC) | DKC is a hybrid cell type capable of dual functionality, i.e. cytotoxicity and antigen presentation, similar to NK cells and DCs, respectively. |
Timeline
- Start date
- 2014-08-01
- Primary completion
- 2016-01-01
- Completion
- 2017-12-01
- First posted
- 2016-08-30
- Last updated
- 2016-08-30
Source: ClinicalTrials.gov record NCT02882659. Inclusion in this directory is not an endorsement.